VBIO Valion Bio, Inc. stock chart & analysis
Conviction 54HealthcareScan · Thu, Nov 19, 2026Valion Bio, Inc. (VBIO) closed at $0.5414 (+7.76%) on Nov 19, 2026. Its latest daily candle is a bullish harami. Price is below its 50-day. RSI(14) 26, -98.6% from its 52-week high, -98.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why VBIO moved
From the StockSetups movers recaps that covered VBIO, newest first. A recap states what was known that day.
- Premarket+41.3%
No headlines are on file for VBIO this morning, and no explanatory press release has been identified. The most recent SEC filings include a September 1 8-K flagged as dilutive (bearish) and a series of 13D/G stake-change filings in early September, suggesting active institutional positioning around the name.
Premarket Movers Sept 30, 2026: CNTB, LGHL, VBIO →
Financials as of Tue, Jun 30, 2026 · quarterly.
VBIO technical analysis
Trend
It closed 63.9% below the 50-day ($1.50). ADX(14) at 13 points to a weak trend — more range than direction.
Momentum
RSI(14) is 26, in oversold territory. The MACD histogram is positive.
Volume and volatility
It trades about $880,344 a day on average. ATR(14) is $0.1532, 28.3% of price — its typical daily range. Bollinger Bands are in a squeeze (2 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (0.41) shows accumulation.
Key levels
The 52-week range is $0.4715 to $39.00; price is 98.6% below the high and 14.8% above the low. The VWAP anchored at the 52-week high is $3.26, above price.
Performance
VBIO returned +6.5% (1 week), -51.7% (1 month), -85.3% (3 months), -98.0% (6 months), -98.2% (year to date).
About Valion Bio, Inc.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Pharmaceutical Preparations · Listed 2021 · 52 employees
Insider activity
SEC Form 4 transactions in VBIO
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Wolf Lisa G Chief Financial Officer · Restricted Stock Units · 2026-06-18 | Exercise | 92 | — | 2026-06-18 | 2026-06-18 |
Wolf Lisa G Chief Financial Officer · Common Stock · 2026-06-18 | Exercise | 92 | — | 2026-06-18 | 2026-06-18 |
Handley Michael K Chief Executive Officer · Common Stock · 2026-05-18 | Exercise | 2.21K | — | 2026-05-18 | 2026-05-20 |
Handley Michael K Chief Executive Officer · Restricted Stock Units · 2026-05-18 | Exercise | 2.21K | $0 | 2026-05-18 | 2026-05-20 |
Lackey Melinda General Counsel & SVP of Legal · Employee Stock Option (Right to Purchase) · 2026-05-01 | Grant | 45K | $0 | 2026-05-01 | 2026-05-04 |
SEC filings
EDGAR filings in VBIO · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.